# Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer

> **NCT00283829** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 30 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** IL2

## Key facts

- **NCT ID:** NCT00283829
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** —
- **Final completion:** 2006-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2007-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00283829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00283829, "Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00283829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*